Google opens AI Mode to prescription drug advertising
Google has begun showing ads for prescription medicines in AI Mode and AI Overviews. The test started in November and is limited to the US market; the formats are text and Shopping.
Google has begun showing ads for prescription medicines in AI Mode and AI Overviews — the company thus confirmed the launch of a test in one of the most tightly regulated segments of global advertising.
Testing of pharmaceutical products, including prescription drugs, started in November 2024 and is limited to the US market, Google's press service said. The news was first reported by the industry publication ADWEEK.
Pharmaceutical segment advertisers have been given the ability to place standard text ads and Shopping ads. In the interface, they will be labeled as "Sponsored" — just as in regular search results.
A Google representative confirmed the launch of the test in an official statement.
"We are testing standard text and Shopping ads in AI Mode and AI Overviews, which we recently expanded to certain categories of pharmaceutical products," the company said in a comment.
What this means for the advertising market
Google's decision marks the arrival of ad formats on a new medium — the generative search interface, which the company is promoting as a replacement for classic search results. Until now, pharmaceutical advertising has remained one of the most difficult categories for any platform due to strict regulation.
Key parameters of the launch:
- Format: standard text ads and Shopping ads
- Platforms: AI Mode and AI Overviews
- Geography: US only
- Labeling: blocks marked "Sponsored"
- Category: pharmaceutical products, including prescription drugs
Opening AI search to prescription medicines means Google is ready to move not only commercial but also fully regulated categories into the generative environment, where control over wording, disclaimers, and target audience is required.
Why Google is doing this
For pharmaceutical brands, appearing in AI Mode and AI Overviews is a new channel for reaching an audience that increasingly gets answers directly in search results without clicking links. If users stop seeing classic ads, advertisers are forced to follow them into new formats.
For now, the test is limited in scope. The company has not disclosed the number of participating advertisers, the list of specific drugs, or the timeline for a possible expansion of the program to other markets.
What's next
Launching in the US is a logical first step: the American pharmaceutical advertising market is one of the largest in the world, and only a few countries allow direct-to-consumer advertising of prescription drugs at all. Expanding to other jurisdictions will require Google to adapt to local regulations.
For the advertising industry, Google's test will serve as an indicator of how quickly generative search turns from an experimental product into full-fledged advertising inventory with highly regulated categories.
Eurasia Marketing will continue to follow the development of the program.
Source: Adweek
More from Сергей Мельник
179 articles
Related articles
- Elvis Presley Song Rights Holders Demand $41.1 Million from Anthropic
- Pinduoduo and Anthropic paid Kazakhstan 8 billion tenge in taxes
- Disney Will Show Super Bowl 2027 Through the Eyes of Star Wars Characters
- Mom's Touch to Open 50 Restaurants in Kazakhstan with Shin-Line
- Prada answered AI slop with a pencil: 6 million views and mice in the style of Disney